Related references
Note: Only part of the references are listed.The role of methysergide in migraine and cluster headache treatment worldwide - A survey in members of the International Headache Society
E. Anne MacGregor et al.
CEPHALALGIA (2017)
The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Carlos M. Villalon et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2017)
A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients
Dikla Gutman et al.
HEADACHE (2016)
5-HT7 Receptors Are Not Involved in Neuropeptide Release in Primary Cultured Rat Trigeminal Ganglion Neurons
Xiaojuan Wang et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2016)
Migraine and risk of cardiovascular disease in women: prospective cohort study
Tobias Kurth et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Migraine and risk of cardiovascular disease in women: prospective cohort study
Tobias Kurth et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
BF-1-A novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs
Beate Schmitz et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis
Chris Cameron et al.
HEADACHE (2015)
Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
Piero Barbanti et al.
HEADACHE (2015)
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
Giuseppe Roberto et al.
CEPHALALGIA (2014)
α-[11C] methyl-L tryptophan-PET as a surrogate for interictal cerebral serotonin synthesis in migraine without aura
Y. Sakai et al.
CEPHALALGIA (2014)
Drugs targeting nitric oxide synthase for migraine treatment
Piero Barbanti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Identifying the Factors Underlying Discontinuation of Triptans
Rebecca E. Wells et al.
HEADACHE (2014)
5-HT7 Receptors Are Involved in Neurogenic Dural Vasodilatation in an Experimental Model of Migraine
Xiaojuan Wang et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2014)
NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models
Deepak K. Bhatt et al.
CEPHALALGIA (2013)
Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs
Martha B. Ramirez Rosas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Genetic association of 5-HT1A and 5-HT1B gene polymorphisms with migraine in a Turkish population
Omer Ates et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice
Luana Lionetto et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan - Basic Science in Relation to Migraine Treatment
Carl Dahlof et al.
HEADACHE (2012)
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Farkkila et al.
LANCET NEUROLOGY (2012)
Chromosome 1p36 in migraine with aura: association study of the 5HT1D locus
Miles D. Thompson et al.
NEUROREPORT (2012)
Sumatriptan transdermal iontophoretic patch (NP101-Zelrix (TM)): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine
Michail Vikelis et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2012)
Association of 5-HTT gene polymorphisms with migraine: A systematic review and meta-analysis
Hua Liu et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - A randomised proof-of-concept trial
Michel D. Ferrari et al.
CEPHALALGIA (2010)
Safety and Pharmacokinetics of NXN-188 After Single and Multiple Doses in Five Phase I, Randomized, Double-Blind, Parallel Studies in Healthy Adult Volunteers
David Vaughan et al.
CLINICAL THERAPEUTICS (2010)
No direct association of serotonin transporter (STin2 VNTR) and receptor (HT 102T > C) gene variants in genetic susceptibility to migraine
Gunjan Joshi et al.
DISEASE MARKERS (2010)
Selective Inhibition of 5-HT7 Receptor Reduces CGRP Release in an Experimental Model for Migraine
Xiaojuan Wang et al.
HEADACHE (2010)
STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses
Markus Schuerks et al.
JOURNAL OF HEADACHE AND PAIN (2010)
Molecular biology of 5-HT receptors
Jason Hannon et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis
Y. Sakai et al.
NEUROLOGY (2008)
5-HT7 receptor-mediated dilatation in the middle meningeal artery of anesthetized rats
Jose A. Terron et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Genetic association study and meta-analysis of the HTR2C Cys23Ser polymorphism and migraine
Agustin Oterino et al.
JOURNAL OF HEADACHE AND PAIN (2007)
[3H]LY334370, a novel radioligand for the 5-HT1F receptor.: II.: Autoradiographic localization in rat, guinea pig, monkey and human brain
VL Lucaites et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2005)
A functional serotonin transporter gene polymorphism is associated with migraine with aura
M Marziniak et al.
NEUROLOGY (2005)
Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks
G Coppola et al.
BRAIN (2005)
Autoradiographic distribution of 5-HT7 receptors in the human brain using [H-3]mesulergine: comparison to other mammalian species
FJ Martin-Cora et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
R Burstein et al.
ANNALS OF NEUROLOGY (2004)
5-HT1F receptor agonists in acute migraine treatment:: a hypothesis
NM Ramadan et al.
CEPHALALGIA (2003)
Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation
KW Johnson et al.
CEPHALALGIA (2003)
Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633
RB McCall et al.
CEPHALALGIA (2002)
Is the 5-HT7 receptor involved in the pathogenesis and prophylactic treatment of migraine?
JA Terrón
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine:: a randomised controlled trial
DJ Goldstein et al.
LANCET (2001)
Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine
B Gomez-Mancilla et al.
CEPHALALGIA (2001)
5-HT1B and 5-HT1D receptors in the human trigeminal ganglion:: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase
MY Hou et al.
BRAIN RESEARCH (2001)
Co-localization of 5-HT1B/1B/1F receptors and glutamate in trigeminal ganglia in rats
QP Ma
NEUROREPORT (2001)
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC)
RS Martin et al.
CEPHALALGIA (2001)
Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein:: effect of selective 5-HT1F receptor agonists and PGF2α
ML Cohen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
The serotonergic agent m-chlorophenylpiperazine induces migraine attacks:: A controlled study
M Leone et al.
NEUROLOGY (2000)
Share Paper
